199 related articles for article (PubMed ID: 32897546)
1. Merging Natural Products: Muraymycin-Sansanmycin Hybrid Structures as Novel Scaffolds for Potential Antibacterial Agents.
Niro G; Weck SC; Ducho C
Chemistry; 2020 Dec; 26(70):16875-16887. PubMed ID: 32897546
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of nucleoside antibacterial natural product antibiotics.
Bugg TDH; Kerr RV
J Antibiot (Tokyo); 2019 Dec; 72(12):865-876. PubMed ID: 31471595
[TBL] [Abstract][Full Text] [Related]
3. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
[TBL] [Abstract][Full Text] [Related]
4. Simplified Novel Muraymycin Analogues; using a Serine Template Strategy for Linking Key Pharmacophores.
Patel B; Kerr RV; Malde AK; Zunk M; Bugg TDH; Grant G; Rudrawar S
ChemMedChem; 2020 Aug; 15(15):1429-1438. PubMed ID: 32476294
[TBL] [Abstract][Full Text] [Related]
5. Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.
Heib A; Niro G; Weck SC; Koppermann S; Ducho C
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861655
[TBL] [Abstract][Full Text] [Related]
6. Analogues of Muraymycin Nucleoside Antibiotics with Epimeric Uridine-Derived Core Structures.
Spork AP; Koppermann S; Schier Née Wohnig S; Linder R; Ducho C
Molecules; 2018 Nov; 23(11):. PubMed ID: 30400295
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.
Kwak SH; Lim WY; Hao A; Mashalidis EH; Kwon DY; Jeong P; Kim MJ; Lee SY; Hong J
Eur J Med Chem; 2021 Apr; 215():113272. PubMed ID: 33607457
[TBL] [Abstract][Full Text] [Related]
8. Improving the N-terminal diversity of sansanmycin through mutasynthesis.
Shi Y; Jiang Z; Lei X; Zhang N; Cai Q; Li Q; Wang L; Si S; Xie Y; Hong B
Microb Cell Fact; 2016 May; 15():77. PubMed ID: 27154005
[TBL] [Abstract][Full Text] [Related]
9. Aminoribosylated Analogues of Muraymycin Nucleoside Antibiotics.
Wiegmann D; Koppermann S; Ducho C
Molecules; 2018 Nov; 23(12):. PubMed ID: 30486316
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
[TBL] [Abstract][Full Text] [Related]
11. Natural Products at Work: Structural Insights into Inhibition of the Bacterial Membrane Protein MraY.
Koppermann S; Ducho C
Angew Chem Int Ed Engl; 2016 Sep; 55(39):11722-4. PubMed ID: 27511599
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of an Antimicrobial Enterobactin-Muraymycin Conjugate for Improved Activity Against Gram-Negative Bacteria.
Rohrbacher C; Zscherp R; Weck SC; Klahn P; Ducho C
Chemistry; 2023 Jan; 29(5):e202202408. PubMed ID: 36222466
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phospho-MurNAc-pentapeptide translocase (MraY) by nucleoside natural product antibiotics, bacteriophage ϕX174 lysis protein E, and cationic antibacterial peptides.
Bugg TD; Rodolis MT; Mihalyi A; Jamshidi S
Bioorg Med Chem; 2016 Dec; 24(24):6340-6347. PubMed ID: 27021004
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial Nucleoside Natural Products Inhibiting Phospho-MurNAc-Pentapeptide Translocase; Chemistry and Structure-Activity Relationship.
Ichikawa S; Yamaguchi M; Matsuda A
Curr Med Chem; 2015; 22(34):3951-79. PubMed ID: 26282943
[TBL] [Abstract][Full Text] [Related]
15. Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics.
Koppermann S; Cui Z; Fischer PD; Wang X; Ludwig J; Thorson JS; Van Lanen SG; Ducho C
ChemMedChem; 2018 Apr; 13(8):779-784. PubMed ID: 29438582
[TBL] [Abstract][Full Text] [Related]
16. Caprazamycins: Biosynthesis and structure activity relationship studies.
Wiker F; Hauck N; Grond S; Gust B
Int J Med Microbiol; 2019 Jul; 309(5):319-324. PubMed ID: 31138496
[TBL] [Abstract][Full Text] [Related]
17. A new nucleosidyl-peptide antibiotic, sansanmycin.
Xie Y; Chen R; Si S; Sun C; Xu H
J Antibiot (Tokyo); 2007 Feb; 60(2):158-61. PubMed ID: 17420567
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Sansanmycin Analogues as Potent
Tran W; Kusay AS; Hawkins PME; Cheung CY; Nagalingam G; Pujari V; Ford DJ; Stoye A; Ochoa JL; Audette RE; Hortle E; Oehlers SH; Charman SA; Linington RG; Rubin EJ; Dowson CG; Roper DI; Crick DC; Balle T; Cook GM; Britton WJ; Payne RJ
J Med Chem; 2021 Dec; 64(23):17326-17345. PubMed ID: 34845906
[TBL] [Abstract][Full Text] [Related]
19. Chemical logic of MraY inhibition by antibacterial nucleoside natural products.
Mashalidis EH; Kaeser B; Terasawa Y; Katsuyama A; Kwon DY; Lee K; Hong J; Ichikawa S; Lee SY
Nat Commun; 2019 Jul; 10(1):2917. PubMed ID: 31266949
[TBL] [Abstract][Full Text] [Related]
20. Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.
Mashalidis EH; Lee SY
J Mol Biol; 2020 Aug; 432(18):4946-4963. PubMed ID: 32199982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
